{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "decreases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "go:GO:0006955",
      "entity_text" : "immunity",
      "entity_type" : "bioprocess"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "uaz:UAZ03404",
      "entity_text" : "cytotoxic T-lymphocyte-associated molecule-4",
      "entity_type" : "protein"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "Since the advent of immunotherapy for the treatment of several neoplastic conditions there has been a rising interest in intrinsic immunity downregulators such as cytotoxic T-lymphocyte-associated molecule-4 (CTLA-4) or programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1).",
  "reading_complete" : "2020-08-04T12:15:51Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-04T12:14:49Z",
  "trigger" : "downregulators",
  "evidence" : [ "immunity downregulators such as cytotoxic T-lymphocyte-associated molecule-4" ],
  "pmc_id" : "6305435",
  "score" : 0
}